Pharmaxis Pty Limited

Promics Pty Limited

Darren Ray March

William Butler Cowden

Bart Michael Eschler

Gavin James Bartell

David P Fairlie

Alan Duncan Robertson

Stephen Maxwell Taylor

Ian Alexander Shiels

Douglas John Francis

Michael Wellesley Whitehouse

Sendaba Gerba

Brett Charlton

Novel phosphotetrahydropyran compounds that mimic mannose-6-phosphate but that are more resistant to phosphatases and mannosidases, and pharmaceutical compositions thereof, are disclosed. These compounds and compositions inhibit T lymphocyte migration from blood to tissues or to other extravascular sites. By inhibiting such migration, these compounds are useful for treating diseases or disorders that are mediated at least in part by such T lymphocyte migration. Such diseases and disorders include rheumatoid arthritis, multiple sclerosis, acute disseminated encephalomyelitis, psoriasis, inflammatory bowel disease, T cell-mediated dermatitis, stromal keratitis, uveitis, thyroiditis, sialitis and type I diabetes.

Mannose-6-phosphonate compounds for the treatment of inflammatory diseases

The invention relates to novel cyclic compounds which have the ability to modulate the activity of G protein-coupled receptors. The compounds preferably act as antagonists. In preferred embodiments, the invention provides cyclic peptidic and peptidomimetic antagonists of C5a receptors, which are active against C5a receptors on polymorphonuclear leukocytes and macrophages. The compounds of the invention are both potent and selective, and are useful in the treatment of a variety of inflammatory conditions.

Cyclic peptides as G-protein-coupled receptor antagonists

The present invention provides phosphotetrahydropyran compounds and the use thereof in treating diseases or conditions that are dependent on T-lymphocyte migration, as well as compositions containing said compounds.

Compounds and methods

Growing community of inventors

Banks, Australia

Darren Ray March